Wie hoch ist der Preis für Vascular Biogenics Ltd. (VBLT)

Preis für Vascular Biogenics Ltd. (VBLT) ist $0.155

Wie hoch ist die Marktkapitalisierung für Vascular Biogenics Ltd. (VBLT)

Marktkapitalisierung für Vascular Biogenics Ltd. (VBLT) ist $7.44M

Vascular Biogenics Ltd. (VBLT) Dividendenrendite

Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.

Jahr	Dividendenrendite	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Dividendenrendite

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Dividendenrendite	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.48%	BE

Unternehmen

Dividendenrendite

Land